☰

Deleo SAS

Connecting the global device fleet to the business

Industry
Medical Devices (Aesthetic)
Headquarters
Fréjus, Provence-Alpes-Côte d'Azur, France
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Deleo SAS's published strategy and is not endorsed by, or produced in cooperation with, Deleo SAS. Company website

Strategic priorities

Deleo SAS designs and builds cryolipolysis and thermal-shock devices from a single facility in Fréjus, Provence-Alpes-Côte d'Azur. The Cristal Pro is a Class IIa medical device in the European Union; in the United States the Cryoskin brand is marketed through distributors such as Artemis Distribution. The installed base is reported at over 2,000 devices globally, supported by approximately 55 employees.

A receivership proceeding (Redressement Judiciaire) opened on 1 August 2022 and was closed on 12 September 2022, signalling the kind of working-capital squeeze that hardware businesses with long component lead times can encounter when a single part slips. Around the same period, the company launched a UK sales subsidiary to manage post-Brexit distribution, indicating that international scaling is continuing alongside the financial tightening.

Marketing materials describe the devices as 'Connected Technology' and reference 'Artificial Intelligence' in R&D, while the technical specifications point to local touchscreen interfaces and firmware updates delivered by service visit or mailed USB stick. Closing the gap between the connected-device story and the operational reality is the underlying thread across Deleo's commercial, regulatory and support priorities.

In the United States, the Cryoskin product is registered under FDA Class I exempt categories such as therapeutic massager, while marketing implies fat-reduction outcomes that would otherwise require Class II 510(k) clearance for lipolysis. The FDA has been increasing scrutiny of body-contouring devices that rely on Class I registration. Building the data layer that supports both EU MDR Post-Market Clinical Follow-up (PMCF) and any future US submission is therefore a regulatory as well as a commercial priority.

Challenges we see

  • Operations Manufacturing

    Smoothing working capital around long-lead components

    Hardware manufacturers purchase compressors, pumps and screens months before revenue is recognised. A Redressement Judiciaire proceeding opened on 1 August 2022 and was closed on 12 September 2022, the kind of event that occurs when a single delayed part freezes working capital.

    Where component lead times are long and assembly is centralised, the gap between paying for parts and receiving device revenue is wide enough that visibility on delivery forecasts becomes a cash-flow question rather than only a procurement question.

  • Operations Operations

    Scaling support across a global installed base

    An installed base of over 2,000 devices is supported by approximately 55 employees, giving a support ratio of roughly 40 machines per employee. Reviews on third-party complaint sites describe clinics with broken devices and limited recourse, which is where distributor-led support shows its limits.

    When the support load is distributed across devices the manufacturer does not see and a workforce sized for a much smaller installed base, the natural next move is to make the device itself report its own state rather than relying on a phone call to start the support cycle.

  • Digital Integration

    Connecting devices to a single operational view

    Marketing describes the devices as 'Connected Technology' and 'Software Intelligence'. Technical documentation shows the user experience is a local touchscreen with preset protocols, and that firmware updates are handled by service visit or by USB stick mailed to the client.

    Where device data lives only inside the unit until someone visits it, R&D cannot observe how the installed base behaves in the field, and a software change reaches the fleet only when the hardware happens to be touched.

  • Compliance Regulatory

    Building regulatory evidence around body-contouring claims

    In Europe the Cristal Pro is a Class IIa medical device cleared for fat cell destruction. In the United States, Cryoskin appears registered under FDA Class I exempt categories such as therapeutic massager, while marketing implies fat-reduction outcomes that sit closer to a Class II 510(k) claim for lipolysis.

    Where the regulatory classification is out of step with the language used to market the device, the underlying clinical evidence becomes the artefact that decides whether the US pathway remains open, narrows or closes.

  • Digital Integration

    Unifying treatment data across product lines and markets

    Deleo operates the Cristal Pro (vacuum cryolipolysis) in Europe and the Cryoskin Peltier wand in the United States through distributors such as Artemis Distribution. Each device line produces data in its own shape, and US data largely resides in distributor systems rather than in Deleo's own environment.

    Where the two product lines and the two market channels do not feed a shared model, the company cannot use its global treatment volume to study efficacy patterns or to support regulatory submissions with its own real-world data.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Predicting working-capital impact of component delays

    Inventory is tracked in the ERP but the financial impact of a delayed component is not visible until the delay becomes a shipment slip. The 2022 receivership episode is the reference event for what a multi-week delay on a single part can do to cash flow.

    Linking ERP data with supplier delivery forecasts and production schedules makes it possible to surface a forecasted cash gap weeks ahead of the event, and to model the procurement or order-mix adjustments that would close it.

    • Infonet company record, Deleo SAS (SIREN 519692115), Redressement Judiciaire 1 August 2022 to 12 September 2022
    • SocieteInfo company record, Deleo SAS (SIREN 519692115)

  2. Adding telemetry to the installed base for proactive support

    Support scales linearly with the installed base while headcount does not, and the device itself gives no signal before it fails. Customer complaints on third-party sites describe clinics left with non-functional equipment and a thin path to resolution.

    Adding a telemetry module to existing devices lets pump pressure, coolant state and compressor vibration reach a central model where degradation patterns can be read, so a replacement part can move towards the clinic before the device stops working.

    • Deleo company page, www.deleo-medical.com
    • Human Optimization Center complaint record, Better Business Bureau

  3. Building a clinic-facing software layer without changing the pricing model

    The Cristal Pro is sold without a per-treatment license fee, which means revenue stops at the device sale. In a contracting aesthetic market, a model that depends on rising unit volume each year is exposed to the demand cycle.

    A clinic software layer that sits beside the device and adds treatment analytics, patient record handling and clinic-side automation opens a recurring revenue stream that does not conflict with the no-license-fee positioning of the hardware.

    • Cristal Pro product brochure, AexelBioMed
    • Deleo company page, www.deleo-medical.com

  4. Connecting the fleet so firmware and protocols can be updated remotely

    Firmware and treatment protocols reach devices by service visit or by mailed USB stick. R&D has no real-time view of how a device in one market is performing compared with a device in another, and bug fixes move through the channel rather than to the device.

    A secure edge gateway on each device, with structured messaging back to a central cloud, lets R&D push firmware updates and new treatment protocols to the whole fleet at once and lets field performance feed back into product development.

    • Cristal Pro product brochure, ASP Medica
    • Deleo R&D description, deleo.co.uk

  5. Collecting regulatory-grade real-world evidence from the installed base

    EU MDR requires continuous Post-Market Clinical Follow-up (PMCF) for the device lifecycle. A future US 510(k) for lipolysis would require clinical evidence. Both are difficult to assemble manually with the current headcount.

    Anonymised treatment data captured from connected devices, with practitioner-side outcome reporting, can populate a regulatory-grade dataset that supports PMCF reporting today and a US submission if the pathway is opened.

    • Cristal Pro product page, www.cristal-bodycontouring.com
    • Deleo company page, www.deleo-medical.com

What we'd propose

  • Enterprise AI

    Supply chain intelligence for component and cash visibility

    An integration between the ERP, supplier data feeds and production scheduling that surfaces a forecasted cash-flow impact when a component slips, and that gives the finance and operations functions one shared view of the pipeline.

    • Supplier and ERP data integration

      Forecasts pulled into one place

      Connect to tier-one supplier systems through API (Application Programming Interface) or EDI (Electronic Data Interchange) feeds to bring delivery forecasts, production schedules and inventory levels into a shared data layer, with the ERP as the reference of record for stock and orders.

    • Predictive cash-flow model

      Liquidity impact forecast weeks ahead

      Build a model that translates a forecasted component delay into a forecasted shipment slip and a forecasted cash gap, so the finance team sees the working-capital impact in the same week that procurement sees the supply signal.

    • Operational command dashboard

      One view across procurement, production and cash

      Provide a dashboard that shows production status, component risk and cash projection in one place, with drill-down to the supplier, part and order level for the operations, finance and leadership teams.

    • A forecasted component delay becomes a forecasted cash impact in the same week, not at month-end.
    • Procurement, operations and finance work from the same part-level view instead of three separate extracts.
    • Working-capital planning moves from reconstruction after the event to anticipation ahead of it.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Predictive maintenance through device telemetry

    A retrofit programme that adds a telemetry module to existing Cristal Pro and Cryoskin devices, so each unit reports the signals that precede a failure and the support organisation can act before the device stops working.

    • Telemetry sensor module

      Health signals from the existing fleet

      Add a non-invasive sensor package that monitors compressor vibration, pump pressure, coolant temperature and Peltier state, with secure cellular or Wi-Fi transport so each device reports its condition without waiting for a service visit.

    • Predictive analytics model

      Failure weeks before it happens

      Train models on fleet data so degradation patterns are visible two to three weeks before a component actually fails, and so the recommended action — replace part, schedule visit, swap unit — is attached to the signal.

    • Support and service dashboard

      Tickets triggered by the device itself

      Provide a dashboard that lists device health scores, open alerts and recommended actions across the fleet, so internal support and distributor support teams work from the same device-level view.

    • Devices report their own state instead of waiting for a clinic to call.
    • Replacement parts move towards the clinic before the unit fails.
    • Support effort shifts from reactive triage to scheduled intervention.

    We've done this before

    See how we do Digital CDMO
  • Digital CDMO

    Secure fleet management and over-the-air updates

    A bidirectional platform that connects each Deleo device to a central cloud through a secure edge gateway, so firmware, treatment protocols and configuration can be updated remotely and field performance can be observed centrally.

    • Edge gateway on each device

      A documented device-cloud bridge

      Specify an edge computing module that handles local data preprocessing, TLS (Transport Layer Security) encryption and store-and-forward behaviour, so each device can communicate with the central platform through a documented, vendor-neutral interface.

    • Over-the-air firmware and protocol deployment

      Updates to the whole fleet at once

      Implement a signed update channel so R&D can deploy bug fixes, cooling algorithm revisions and new treatment protocols to the entire fleet in one operation, with rollback if a release does not behave as expected on a subset of devices.

    • Fleet analytics and configuration console

      Global view, local control

      Provide a console that shows treatment volumes, device utilisation, geographic distribution and firmware status across the fleet, and that lets support and product teams change configuration centrally when a clinical protocol is updated.

    • Firmware and protocol updates reach the fleet in hours rather than at the next service visit.
    • Field performance feeds back into R&D as data rather than as anecdotal feedback.
    • Configuration changes that affect clinical use can be tracked and rolled back centrally.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Real-world evidence platform for EU MDR and US regulatory submissions

    A clinical evidence infrastructure that captures anonymised treatment data from the connected fleet and turns it into the regulatory artefact base for EU MDR Post-Market Clinical Follow-up (PMCF) and for any future US 510(k) submission.

    • Automated PMCF data capture

      Compliance without manual follow-up

      Capture device health, usage and outcome data continuously from the connected fleet, and push practitioner surveys at defined treatment milestones, so PMCF evidence is generated by the system rather than assembled by phone.

    • Real-world evidence data repository

      Anonymised treatment records at scale

      Consolidate anonymised treatment data across both the European and US installed bases into a regulatory-grade repository, structured so that safety and efficacy analyses can be run against it as a single cohort.

    • Audit trail and submission packaging

      Evidence traceable from claim to record

      Maintain an immutable audit trail covering device configuration, firmware version, calibration state and treatment parameters, so a regulatory submission or inspection can be answered from the record rather than reconstructed for it.

    • EU MDR PMCF evidence is produced continuously rather than assembled on demand.
    • A future US 510(k) submission draws on the company's own installed-base data rather than a parallel trial.
    • Each regulatory claim is traceable to the device record, the firmware state and the outcome that supports it.

    We've done this before

    See how we do Digital Lab
  • Agents

    AI agents for regulatory and clinical document work

    Narrow, reviewable agents that take the repetitive part of regulatory and clinical document work — drafting PMCF summaries, populating 510(k) sections from source records, and finding every controlled document that a standards change touches — with a named reviewer approving each output.

    • Drafting from source records

      First drafts from system data

      Generate first drafts of PMCF summaries, clinical evaluation sections and 510(k) submission content directly from the underlying device, treatment and quality records, so the regulatory author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against the relevant regulatory template and the company's own checklist, returning missing or inconsistent sections before the document enters the formal review queue.

    • Change impact search across the document set

      Which documents a change touches

      When a standard, a clinical guideline or a treatment protocol changes, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one.

    • PMCF and 510(k) drafts start from system data instead of from a blank page.
    • Submission packages arrive at review more complete, so review cycles shorten.
    • Every agent output is traceable to the records it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Deleo SAS's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Device fleet connectivity 25 → 80
Marketing describes connected capability while the technical reality is a local touchscreen interface. The target state moves device data out of the unit and into a shared operational view.
Predictive analytics 15 → 75
R&D references AI capability but the data infrastructure to train and validate predictive models is not in place. The target state covers cooling-algorithm training and degradation prediction on real fleet data.
Supply chain visibility 30 → 85
The ERP tracks inventory but does not forecast the cash-flow impact of a delayed component. The 2022 receivership episode illustrates the gap between tracking and anticipating.
Regulatory data systems 40 → 90
EU MDR PMCF is currently manual and the US classification question is unresolved. The target state is a connected, audit-traceable dataset that supports both regimes.
Customer intelligence 20 → 70
End-user feedback in the US reaches Deleo through distributors. The target state is direct device-level insight into how each unit is used and how treatments unfold.
Recurring revenue model 10 → 60
Revenue currently stops at the device sale. The target state adds a software layer that the clinic values in its own right, without changing the no-license-fee hardware positioning.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Deleo SAS, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].